Purpose/Objective: The XRAD225Cx is a small animal radiotherapy device using a medium energy beam (225 kVp) and small circular fields. In addition to the half-value layers and the absolute dose rate, the commissioning of this equipment requires relative dose measurements such as percentage depth dose (PDD), Output Factor (OF) and Tissue Maximum Ratio (TMR). The aim of this study was to compare two media and four detectors to determine the optimal conditions to perform these relative measurements. Materials and Methods: RW3 material is known not to be waterequivalent at medium energy for absolute dose measurements. To evaluate the impact of this medium for relative dose measurements, PDDs were obtained in water and RW3 for a 10x10 cm 2 field with a plane-parallel ionization chamber and EBT2 Gafchromic films. Simulated PDDs were generated using a GATE Monte Carlo model of the irradiator. To study the influence of the detector, four dosimeters (an IBA SFD diode, a PTW PinPoint 31014 microchamber, EBT2 films and a PTW-23342 plane-parallel chamber) were compared for OFs, PDDs and TMRs in water and/or RW3 depending on the dosimeter sealing. Measurements were performed in small fields (20, 15, 10, 8, 5 and 2.5 mm in diameter). OFs, PDDs, and TMRs were also computed with the Monte Carlo model. Results: Measured and simulated PDDs were similar in water and RW3. Regardless of media and detectors, simulated and measured OFs showed no differences down to a diameter beam of 5 mm. For the smallest beam (2.5 mm),ionization chambers yielded large discrepancies (up to -22%) compared to SFD and EBT2 measurements and Monte Carlo simulations. This is due to the size of the sensitive volume of chambers compared to beam diameter. For PDDs and TMRs, measurement accuracy depends on spatial resolution in depth of the detector. Therefore, PinPoint chamber was not used. Plane ionization chamber and film measurements were closed to Monte Carlo computed results. SFD diode results showed significant discrepancies (up to 9%) due to the important variation in the relative energy response of the diode at 225 kVp. Conclusions: For relative measurements, RW3 can be used instead of water at 225 kVp for convenient considerations. For OFs, all studied detectors may be used down to a beam diameter of 5 mm. For smaller beams, measurements should be performed with the SFD diode or Gafchromic films. For PDDs and TMRs, plane ionization chamber can be used down to a beam diameter of 5 mm. Gafchromic films are suitable whatever the beam diameter. Purpose/Objective: To assess the sensitivity of three different commercially available dosimetry systems in detecting treatment delivery errors during helical tomotherapy pre-treatment verification. Materials and Methods: Three dosimeters 1) MatriXX Evolution (IBA®) with OmniPro-ImRT software 2) ArcCheck®(Sun Nuclear®) with SNC Patient software 3) EDR-2 film with cheese phantom and RIT software were considered. A head and neck helical tomotherapy plan was edited to introduce known systematic errors in couch speed, gantry speed, gantry start angle, and projection time. The magnitude of each introduced error was +2% and +4% relative to the original treatment plan. All measurements were performed at the same time to minimize day-to-day and phantom setup variations. For each dosimeter the measured dose for the original plan was compared to each altered plan with a Gamma analysis using 3%/3 mm pass criteria. Results: The gamma pass rates are shown in Table 1 . In each case an introduced error resulted in a decreased gamma pass rate. Results were comparable across the three detectors. Sensitivity to couch speed, gantry speed, and start gantry angle were similar for each detector. All detectors were most sensitive to projection time errors.
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Conclusions:
All three dosimetry systems were sensitive to each introduced error. Additional work is underway to assess the impact of these errors on treatment plans and to include systematic/random error in MLC and jaw position. This work will also help to establish meaningful tolerance levels for quality assurance. Purpose/Objective: To evaluate the accuracy of the dose calculation algorithm for the target (bones) and some sensitive structures (lungs, eyes, heart, kidneys) in total marrow irradiation (TMI) performed with helical tomotherapy (HT). Materials and Methods: Thermoluminescent detectors (TLDs) were used to measure delivered doses. Dose optimization was performed with the HT treatment planning system. Doses were calculated for selected points in the target -bones (9 TLDs), in the central lung (11 TLDs) and in eye, heart, kidney (4 TLDs) in an anthropomorphic phantom. The target dose was 12 Gy to the skeletal bone. A dose of 2 Gy was delivered 6 times. We compared the calculated dose to the measured dose. Results: For each dosimetric point, the measured value was averaged and corrected by the MVCT scan value and converted according to the calibration factors. The mean difference between the measured and calculated dose for the bone TLDs was 1.2% (with a range of -4.2% to +5.0% for individual detectors included in this group), indicating that the measured dose was higher than the calculated dose. For the lung-TLD group of detectors, the corresponding difference was -1.9% (range, -9.0% to +7.6%). At 11 points, the measured dose was lower than the calculated dose, with the largest differences observed in the region located in the kidney (-9.2%) and lungs (-9.0%). . Subsequently, the corresponding PD images were acquired. Performance of the configured PD solution was evaluated with respect to: (i) OFs by calculating the rel. difference (acquired vs. predicted PD image) of the central axis dose values, (ii) beam profile correction by calculating the mean rel. difference of the central cross-line profiles in the flat field region (80% area within field limits) and (iii) backscatter correction by calculating the maximum rel. difference of the central half in-line profile in the flat field region (Fig. 1a) .
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Results:
The analysis of 6MV Clinac data (Fig. 1b) revealed that for OFs and beam profile correction the rel. differences were found to be within ±1% for all field sizes, while the backscatter correction was found to be within ±1.5% for field sizes up to 15 x 15 cm 2 . For the 6MV Unique data and 15MV Clinac data the same limits were met except for the backscatter correction of the smallest field size (3 x 3 cm 2 ). The 18MV Clinac data revealed rel. differences smaller than ±1% for both OFs and beam profile correction, while not all field sizes (4 x 4 cm 2 and 5 x 5 cm 2 ) met the ±1.5% limit for the backscatter correction.
Conclusions:
The use of generic configuration data appears to be feasible for the Varian PD solution allowing for a simplified configuration process and the easy implementation of essential improvements. Further data at high beam energies as well as for dynamic MLC fields (IMRT and VMAT) are required to support the promising results obtained in this preliminary study. 
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Materials and Methods:
On Varian TrueBeam linac, the PV-aS1000 detector response was investigated for 6 and 10 MV FFF beams. With an adequate source to detector distance, e.g. SDD=150 cm, even with the maximum dose rate of 1400 and 2400 MU/min the integrated image does not present saturation. This allows its usage for dosimetric evaluations also for FFF beams. The GLAaS algorithm was originally developed to convert portal imager integrated readings into absorbed dose to water, and was validated for IMRT and RapidArc (the Varian VMAT) pre-treatment quality assurance for standard flattened beams. The algorithm was adapted to FFF beams and validated for open as well as for modulated beams. In this study it was used to evaluate RapidArc pre-treament acquisitions. Five different clinical FFF RapidArc plans were selected and recalculated for both 6 and 10 MV FFF. The maximum dose rate was set for each energy. Dose prescriptions ranged from 7 to18 Gy/fraction. Pre-treatment QA deliveries were performed on four different TrueBeam machines (two equipped with a high-definition MLC, HD-120MLC, and two with a standard Millenium 120-MLC). QA evaluation was based on gamma index,using distance to agreement and dose difference criteria of 3mm/3% and 2mm/2%. 2D dose maps were evaluated also through profiles. Results: The percentage of points passing the gamma criteria (gamma agreement index GAI) were collected for all deliveries.For 3mm/3% criteria, GAI evaluated on the field area was 97.9±2.5% and and 98.6±1.6% for 6 and10 MV FFF respectively.For 2mm/2% criteria, GAI evaluated on the field area was 92.0±3.5% and and 96.6±4.3% for 6 and10 MV FFF respectively. Conclusions: The possibility to use the Portal Vision as pre-treatment QA for RapidArc for FFF beams gives advantages that can be summarised in three points: 1) verification of absorbed dose calculation, 2) fast acquisition, 3) improved resolution at SDD=150 cm, particularly interesting in hypofractionated treatment, where small fields are mostly used. Gamma results presented fully satisfactory results in line with standard flattened beams.
